drugset
drugset / Trial / NCT02684318

Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors

NCT02684318 ↗

Phase 1/2 Unknown 100 enrolled Poveda, Andrés, M.D. AstraZeneca · collabPharmaMar · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 in combination with olaparib in patients with advanced solid tumors.

Timeline

Start
2015-07
Primary completion
2019-07
Completion
2019-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurbinectedin Other / unclassified 1 mg/m2 Intravenous
Subject Lurbinectedin Other / unclassified 1.5 mg/m2 Intravenous
Subject Lurbinectedin Other / unclassified 2 mg/m2 Intravenous
Subject Lurbinectedin Other / unclassified 3 mg/m2 Intravenous
Subject Olaparib Small molecule 100 mg Oral
Subject Olaparib Small molecule 150 mg Oral
Subject Olaparib Small molecule 200 mg Oral
Subject Olaparib Small molecule 250 mg Oral
Subject Olaparib Small molecule 300 mg Oral

Indications

breast cancer cancer of unknown primary site endometrial cancer ovarian cancer